Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies.

Laurence Zitvogel Lisa Derosa Guido Kroemer

Published in: Blood cancer discovery (2023)

In patients with multiple myeloma, completion of mRNA-based vaccination schemes failed to yield detectable SARS-CoV-2 Omicron-neutralizing antibodies and S1-RBD-specific CD8+ T cells in approximately 60% and 80% of the cases, respectively. Patients who develop breakthrough infections exhibited very low levels of live-virus neutralizing antibodies and the absence of follicular T helper cells. See related article by Azeem et al., (9) . See related article by Chang et al., (10) .

Keyphrases

sars cov
multiple myeloma
respiratory syndrome coronavirus
induced apoptosis
dengue virus
copy number
cell cycle arrest
zika virus
oxidative stress